jili777 register

NEW YORK--(BUSINESS WIRE)--Nov 25, 2024-- Athena Technology Acquisition Corp. II (NYSE American: ATEK.U, ATEK, ATEK WS) (“ATEK” or the “Company”) received an official notice of noncompliance (the “NYSE American Notice”) from NYSE Regulation (“NYSE”) stating that the Company is not in compliance with NYSE American continued listing standards due to the failure to timely file the Company’s Form 10-Q for the quarter ended September 30, 2024 (the “Delinquent Report”) by the filing due date of November 19, 2024 (the “Filing Delinquency”). The Company intends to file the Delinquent Report in the near future, however, there is currently no anticipated date for when such Filing Delinquency will be cured via the filing of the Delinquent Report. The Company expects, however, to regain compliance with the NYSE American continued listing standards once the Delinquent Report has been filed. In the interim, the NYSE American Notice has no immediate effect on the listing or trading of the Company’s Class A common stock listed on NYSE American. There can be no assurance that the Company will ultimately regain and remain in compliance with all applicable NYSE American listing standards. About Athena Technology Acquisition Corp. II Athena Technology Acquisition Corp. II (NYSE American: ATEK.U, ATEK, ATEK WS), incorporated in Delaware, is a special purpose acquisition company incorporated for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses or entities. ATEK is the third SPAC founded by Isabelle Freidheim, who also serves as its Chief Executive Officer, with Kirthiga Reddy as President and Jennifer Calabrese as Chief Financial Officer. Forward-Looking Statements Certain statements made in this press release are not historical facts but may be considered “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), Section 21E of the Securities Exchange Act of 1934, as amended, and the “safe harbor” provisions under the Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook,” “intend,” or continue or the negatives of these terms or variations of them or similar terminology or expressions that predict or indicate future events or trends or that are not statements of historical matters. These statements are based on the current expectations of the Company’s management and are not predictions of actual performance. Such statements may include, but are not limited to, statements regarding the Company’s plan to file the Delinquent Report within the provided cure period to regain compliance with the NYSE American continued listing standards. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on, by any investor as a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of the Company. These statements are subject to a number of risks and uncertainties, and actual results may differ materially. These risks and uncertainties include, but are not limited to: the Company’s ability to file the Delinquent Report within the Initial Cure Period to regain compliance with the NYSE American continued listing standards; general economic, political and business conditions; the number of redemption requests made by the Company’s stockholders in connection with a potential business combination; the outcome of any legal proceedings that may be instituted against the Company; the risk that the approval of the Company’s stockholders for a potential transaction is not obtained; expectations related to the terms and timing of a potential business combination; failure to realize the anticipated benefits of a business combination; the risk that a business combination may not be completed by the Company’s business combination deadline and the potential failure to obtain an extension of its business combination deadline in the Company’s upcoming Annual Meeting of Stockholders; costs related to a business combination; and other risks that will be detailed from time to time in filings with the SEC, including those risks discussed under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023 filed with the SEC on September 27, 2024 and in subsequently filed Quarterly Reports on Form 10-Q. The foregoing list of risk factors is not exhaustive. There may be additional risks that could also cause actual results to differ from those contained in these forward-looking statements. In addition, forward-looking statements provide the Company’s expectations, plans or forecasts of future events and views as of the date of this press release. And while the Company may elect to update these forward-looking statements in the future, the Company specifically disclaims any obligation to do so, except as required by law. These forward-looking statements should not be relied upon as representing the Company’s assessments as of any date subsequent to the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements. Nothing herein should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that the results of such forward-looking statements will be achieved. View source version on businesswire.com : https://www.businesswire.com/news/home/20241125554143/en/ CONTACT: Bevel PR Athena@bevelpr.com KEYWORD: UNITED STATES NORTH AMERICA NEW YORK INDUSTRY KEYWORD: BANKING PROFESSIONAL SERVICES FINANCE SOURCE: Athena Technology Acquisition Corp. II Copyright Business Wire 2024. PUB: 11/25/2024 04:05 PM/DISC: 11/25/2024 04:05 PM http://www.businesswire.com/news/home/20241125554143/enWall Street's rally stalls as Nasdaq pulls back from its recordNone

Once again, Newsom gets Trumped by the calendar.

PDUFA goal date is July 27, 2025 COPENHAGEN, Denmark, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the U.S. Food & Drug Administration (FDA) has accepted for review its supplemental Biologics License Application (sBLA) in adult growth hormone deficiency (GHD) for TransCon hGH (lonapegsomatropin-tcgd; marketed as SKYTROFA ® for pediatric GHD). The FDA set a Prescription Drug User Fee Act (PDUFA) goal date of July 27, 2025. "This marks another step towards achieving our objective to expand SKYTROFA's label beyond pediatric GHD and expand its reach to address new groups of patients,” said Jan Mikkelsen, Ascendis Pharma's President and Chief Executive Officer. "Adult GHD is an undertreated condition associated with significant comorbidities and higher annual healthcare costs compared to the 5-10% of patients who receive treatment, indicative of the high unmet need.” The sBLA submission is based on results from foresiGHt, a Phase 3 randomized, parallel-arm, placebo-controlled (double-blind) and active-controlled (open-label) trial that compared the efficacy and safety of weekly TransCon hGH with weekly placebo and daily human growth hormone (hGH) in adults with GHD. The trial evaluated 259 adults with GHD aged 23 to 80 years old, randomized 1:1:1, titrated to receive a target fixed dose of TransCon hGH, placebo, or daily hGH based on age and oral estrogen intake with approximately equivalent hGH mg/week for TransCon hGH and daily hGH. TransCon hGH demonstrated superiority on its primary efficacy and key secondary efficacy endpoints at Week 38, with TransCon hGH-treated participants showing a statistically significant reduction from baseline in trunk fat and increase in total body lean mass at Week 38 compared to placebo. In the trial, TransCon hGH was generally safe and well tolerated, with no discontinuations related to study drug and with comparable safety and tolerability to daily hGH treatment. About Adult Growth Hormone Deficiency Growth hormone plays an essential role in the health of children and adults, promoting normal growth in children and maintenance of normal body composition and cardiometabolic health throughout adulthood. In adults, growth hormone boosts protein production, promotes fat utilization, enhances muscle mass, and helps regulate blood sugar levels. Adult GHD is a condition in which an individual's body does not produce enough growth hormone. Symptoms and morbidity can include central obesity, metabolic syndrome, decreased bone density, alterations in lipid profile and markers of cardiovascular risk, fatigue, general weakness, lack of muscle tone, and psychological symptoms such as cognitive impairment, social isolation, lack of motivation, and depression. 1 About Ascendis Pharma A/S Ascendis Pharma is applying its innovative TransCon technology platform to build a leading, fully integrated biopharma company focused on making a meaningful difference in patients' lives. Guided by its core values of Patients, Science, and Passion, Ascendis uses its TransCon technologies to create new and potentially best-in-class therapies. Ascendis is headquartered in Copenhagen, Denmark and has additional facilities in Europe and the United States. Please visit ascendispharma.com to learn more. Forward-Looking Statements This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding Ascendis' future operations, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to (i) the PDUFA goal date for SKYTROFA, (ii) Ascendis' objective to expand SKYTROFA's label and reach to address new groups of patients, (iii) Ascendis' ability to apply its TransCon technology platform to build a leading, fully integrated biopharma company, and (iv) Ascendis' use of its TransCon technologies to create new and potentially best-in-class therapies. Ascendis may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions, expectations, and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements that Ascendis makes, including the following: dependence on third party manufacturers, distributors and service providers for Ascendis' products and product candidates; unforeseen safety or efficacy results in Ascendis' development programs or on-market products; unforeseen expenses related to commercialization of any approved Ascendis products; unforeseen expenses related to Ascendis' development programs; unforeseen selling, general and administrative expenses, other research and development expenses and Ascendis' business generally; delays in the development of its programs related to manufacturing, regulatory requirements, speed of patient recruitment or other unforeseen delays; Ascendis' ability to obtain additional funding, if needed, to support its business activities; the impact of international economic, political, legal, compliance, social and business factors. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Ascendis' business in general, see Ascendis' prospectus supplement filed on September 20, 2024 and Ascendis' current and future reports filed with, or submitted to, the U.S. Securities and Exchange Commission (SEC), including its Annual Report on Form 20-F filed with the SEC on February 7, 2024. Forward-looking statements do not reflect the potential impact of any future licensing, collaborations, acquisitions, mergers, dispositions, joint ventures, or investments that Ascendis may enter into or make. Ascendis does not assume any obligation to update any forward-looking statements, except as required by law. Ascendis, Ascendis Pharma, the Ascendis Pharma logo, the company logo, TransCon, and SKYTROFA ® , are trademarks owned by the Ascendis Pharma group. © December 2024 Ascendis Pharma A/S.Woodward Earnings Review: Q4 SummaryGophers football adds Nebraska wideout Malachi Coleman via portal

Sharks make roster moves ahead of game vs. L.A. KingsLeading Lebanese soccer player Celine Haidar is in a medically induced coma after she was critically wounded in an Israeli strike near her home in Beirut's southern suburbs, her international championship prospects on hold. Captain of her club team and already included in the national youth team twice, the 19-year-old refused to allow her training to be interrupted by Israel's bombardment, even as her own family fled to a mountain town east of Beirut. She convinced her parents to let her return home alone so she could continue training, assuring them she would leave every time the Israeli army issued an evacuation warning for a neighbourhood it was intending to bomb. But last Saturday, she missed the warning. She was asleep when the Israeli military spokesman posted an evacuation warning for her neighborhood. Her parents called her and urged her to leave immediately, but time was short. An Israeli warplane struck as she leapt onto her motorbike. She was hit by shrapnel, which left her with severe brain injuries, including multiple skull fractures and brain bleeding. The Israeli military was not immediately available to comment on the strike. She is now in an intensive care unit at Saint George Hospital in Beirut, connected to monitors and a breathing tube, with her head bandaged, according to her coach Samer Barbary. Her parents, Abbas Haidar and Sanaa Shahrour, stand watch over her, struggling to comprehend the calamity that befell their daughter and praying for a miracle. Over 15,000 wounded by Israeli strikes "I never thought I would have a daughter like her," her father said, his voice heavy with emotion. "She has dreams and strength. She always told me, 'You'll see what I will accomplish tomorrow.'" She is among over 15,000 people wounded by Israeli strikes over the past year, with bombardment of Beirut's suburbs escalating dramatically over the last two months. The Israeli military says it is striking infrastructure belonging to armed group Hezbollah, which counted the suburbs, as well as south and east Lebanon, as its strongholds. More soccer coverage More than 670 women and 230 children are among the more than 3,500 people killed, Lebanon's health ministry says. Haidar's teammates have hung a poster at their training field saying: "We are waiting for you." "She is the cornerstone of our team," her teammate Lama Abdin, 18, said. "But we will play for her. We will achieve her big dreams." Head coach Barbary said Haidar had already represented Lebanon twice with the under-19 national team which won the 2022 West Asia cup that was held in Lebanon. She was already selected for the senior national team and was expected to be selected for the upcoming West Asia championship, he said. Even though doctors say they do not know when she will wake up again, her mother, Sanaa, has refused to give up hope. "I am waiting for you. Don't give up. You are a hero. Every night, I see you in my dreams, coming back to me," she told Reuters.Brazil stocks lower at close of trade; Bovespa down 1.59%

Stock market today: Wall Street climbs as Nvidia swings, bitcoin rises and Alphabet sinksCatching a 71-metre rocket mid-air and the first-ever private spacewalk

FSK Completes Public Offering of $100 million 6.125% Unsecured Notes Due 2030

SNOOKER legend Ronnie O'Sullivan has criticised the up-and-coming generation of young players for their lack of work ethic. O'Sullivan is a member of snooker's famous 'Class of 92' alongside John Higgins and Mark Williams . The trio turned professional during the 1992-93 season and went on to dominate the sport for years. According to the Rocket himself, the main attribute that set them apart from their rivals was their work ethic. O'Sullivan said: "I think about when we were juniors, there was such a good Pro-Am circuit. "I remember I'd travel to Wales, Sheffield, Leicester, and play against people like Ken Doherty, Peter Ebdon and Anthony Hamilton. Read More in Snooker "I would have only been 11 or 12 at the time. We were kids, me and Mark. Higgins never ventured out of Scotland – he appeared when he was around 14. I think that was the first we'd heard of John Higgins. "But me and Mark were always playing in Pro-Ams and junior events, so I think we had a really good schooling "There were no phones, there was no Instagram. There was a different work ethic. "We were much more seasoned, more purist. The way we came into it, you were maybe a lot more focused." Most read in Snooker CASINO SPECIAL - BEST CASINO WELCOME OFFERS O'Sullivan went on to claim that many up-and-coming snooker players lack the same work ethic which has led to them thinking they are better than they actually are. He continued: "We had that professionalism about us that maybe the newer generation [don't have]. "Maybe the newer generation have had it too easy. When we came through the amateur circuit you had to earn your way through it. "Now a lot of players turn pro, they think they're good, but really they're not. "We had to come through the hard way – the juniors, the amateurs, then professionals and work our way up through it. "So have a lot of other players, but we were in a golden era for snooker I suppose." FROM his lightning breaks to blasts at officials, Ronnie O'Sullivan has fired snooker into the spotlight. The seven-time world champion makes almost as big an impact away from the table as on it. O'Sullivan has three children - two daughters and a son. And the Rocket's on-off relationship with British actress Laila Rouass has also hit the headlines. He has opened up on battles with his weight and addiction . While the controversial cueist reckons he wasted NINE YEARS of his career by partying too hard. Despite being worth £14million , O'Sullivan is renowned for his love of canal boats and snubbing flashy cars . His rivalry with fellow star Judd Trump has been branded 'snooker's greatest feud'. And Ali Carter had his nose knocked out of joint by the Rocket in their infamous 'Snotgate' row. Check out all our latest Ronnie O'Sullivan articles.Hyundai offers free Tesla adapters to its U.S. customers